Influence of baseline FEV1 on improvement in severe eosinophilic asthma with mepolizumab
F. Gonzalez Barcala (Santiago de Compostela, Spain), M. Blanco-Aparicio (Galicia, Spain), A. Gómez-Bastero (Sevilla, Spain), G. Soto-Campos (Jerez, Spain), D. Bañas Conejero (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2124
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Gonzalez Barcala (Santiago de Compostela, Spain), M. Blanco-Aparicio (Galicia, Spain), A. Gómez-Bastero (Sevilla, Spain), G. Soto-Campos (Jerez, Spain), D. Bañas Conejero (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain). Influence of baseline FEV1 on improvement in severe eosinophilic asthma with mepolizumab. 2124
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|